Journal ArticleOPEN ACCESS

Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma

British Journal of Cancer (2004) 90(6) 1125-1128
DOI: 10.1038/sj.bjc.6601700
17Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The recommended phase II dose of paclitaxel 180 mgm-2 given as a 3-h infusion followed by nedaplatin 100 mgm-2 in a 1-h infusion every 3-4 weeks was determined in 52 chemo-naive patients with unresectable squamous cell carcinoma (SCC), with a promising response rate for lung SCC of 55%. © 2004 Cancer Research UK.

Author supplied keywords

Cite

CITATION STYLE

APA

Sekine, I., Nokihara, H., Horiike, A., Yamamoto, N., Kunitoh, H., Ohe, Y., … Saijo, N. (2004). Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma. British Journal of Cancer, 90(6), 1125–1128. https://doi.org/10.1038/sj.bjc.6601700

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free